Genmab A/S (GE9) Stock Price & Analysis

15 Followers

GE9 Stock Chart & Stats

€478.10-€1.20(-0.25%)

At close: Nov 11 5:30 PM GMT+1

Day’s Range: EUR 468.30 - EUR 480.80
52-Week Range: EUR 203.50 - EUR 521.80
Previous Close: EUR 479.30
Volume: N/A
Average Volume (3M): 327
Market Cap: EUR 28.63B
Enterprise Value: EUR 168.19B
Total Cash (Recent Filing): EUR 3.23B
Total Debt (Recent Filing): EUR 143.00M
Price to Earnings (P/E): 44.5
Beta: 0.86
Next Earnings: Feb 24, 2027 (Est.)
EPS Estimate: 2.02
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Genmab A/S News

Bicara Therapeutics price target lowered to $37 from $39 at BTIG

BTIG lowered the firm’s price target on Bicara Therapeutics (BCAX) to $37 from $39 and keeps a Buy rating on the shares after its Q3 results. The firm states the

1d agoBCAX GMAB

Genmab reports 9M revenue $3.24B vs. $2.66B last year

Royalty revenue was $2.7B in the first nine months of 2026 compared to $2.22B in the first nine months of 2025, an increase of $480M, or 22%. The increase in

6d agoGMAB GE9

Genmab backs 2026 financial guidance

11:05 EST Genmab (GMAB) backs 2026 financial guidance Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by

6d agoGMAB GE9

Genmab: Positive Phase III Results and Pipeline Potential Drive Price Target Raise to $4,400

Bank of America Securities analyst Charlie Haywood has reiterated their bullish stance on 0MGB stock, giving a Buy rating on October 29. Charlie Haywood gave his rating based on several

1w agoGMAB GE9

Genmab price target raised to DKK 4,400 from DKK 4,200 at BofA

BofA analyst Charlie Haywood raised the firm’s price target on Genmab (GMAB) to DKK 4,400 from DKK 4,200 and keeps a Buy rating on the shares. After 3/3 positive Phase

1w agoGMAB GE9

Genmab price target raised to $57 from $42 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Genmab (GMAB) to $57 from $42 and keeps an Equal Weight rating on the shares. Published first on TheFly – the ultimate

1w agoGMAB GE9

Genmab price target raised to $80 from $58 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab (GMAB) to $80 from $58 and keeps a Buy rating on the shares. Published first on TheFly – the

1w agoGMAB GE9

Bicara Therapeutics downgraded to Sell at Goldman on lower ficera outlook

As previously reported, Goldman Sachs downgraded Bicara Therapeutics (BCAX) to Sell from Neutral with a price target of $8, down from $20. The firm is decreasing peak share estimates for

1w agoBCAX GMAB

Bicara Therapeutics price target lowered to $24 from $33 at Wedbush

Wedbush analyst David Nierengarten lowered the firm’s price target on Bicara Therapeutics (BCAX) to $24 from $33 and keeps an Outperform rating on the shares. Relevant to Bicara, Genmab’s (GMAB)

2w agoBCAX GMAB

Genmab price target raised to $70 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $70 from $50 and keeps a Buy rating on the shares. The company announced positive top-line results from the

2w agoGMAB GE9

Genmab rises 29.2%

Genmab (GMAB) is up 29.2%, or $13.04 to $57.71. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on

2w agoGMAB GE9

Genmab: Advancing Oncology Assets Support Buy Rating and Unchanged $50 Price Target

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on GMAB stock, giving a Buy rating on October 19. Ram Selvaraju has given his Buy rating due to a

2w agoGMAB GE9

Genmab: Robust Oncology Data Drive Buy Rating and Price Target Increase to 3,200 DKK

Analyst Charlie Haywood of Bank of America Securities reiterated a Buy rating on Genmab A/S, boosting the price target to DKK3,200.00. Charlie Haywood has given his Buy rating due to

2w agoGMAB GE9

Genmab Maintained at Buy as DARZALEX Strength and Oncology Pipeline Support Unchanged $50 Price Target

Genmab, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $50.00

3w agoGMAB GE9

GE9 FAQ

What was Genmab A/S’s price range in the past 12 months?

Genmab A/S lowest stock price was €203.50 and its highest was €521.80 in the past 12 months.

What is Genmab A/S’s market cap?

Genmab A/S’s market cap is €28.63B.

When is Genmab A/S’s upcoming earnings report date?

Genmab A/S’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 104 days.

How were Genmab A/S’s earnings last quarter?

Genmab A/S released its earnings results on Nov 05, 2026. The company reported €4.933 earnings per share for the quarter, beating the consensus estimate of €3.128 by €1.805.

Is Genmab A/S overvalued?

According to Wall Street analysts Genmab A/S’s price is currently Undervalued.

Does Genmab A/S pay dividends?

Genmab A/S does not currently pay dividends.

What is Genmab A/S’s EPS estimate?

Genmab A/S’s EPS estimate is 2.02.

How many shares outstanding does Genmab A/S have?

Genmab A/S has 62,405,853 shares outstanding.

What happened to Genmab A/S’s price movement after its last earnings report?

Genmab A/S reported an EPS of €4.933 in its last earnings report, beating expectations of €3.128. Following the earnings report the stock price went up 0.5%.

Which hedge fund is a major shareholder of Genmab A/S?

Currently, no hedge funds are holding shares in DE:GE9

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genmab A/S

Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S (GE9) Earnings & Revenues

Historic Earnings Reports

GE9 Stock 12 Month Forecast

Average Price Target

€502.76▲(5.16% Upside)

Past 12 Months12 Month ForecastFeb2026Nov2026

High€601.97

Average€502.76

Low€334.43

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	12	5	5
Technical Analysis	3	5	2
Moving Averages	9	0	3

Technical Analysis >

Similar Stocks

Stocks similar to DE:GE9
Company	Price & Change	Follow
GB:0MGBGenmab A/S
GB:GSKGlaxoSmithKline
GB:AZNAstraZeneca
GB:HIKHikma Pharmaceuticals

Compare DE:GE9 Stocks >

Ownership Overview

10.82% Mutual Funds
0.35% Other Institutional Investors
76.23% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

GE9 Stock Chart & Stats

Genmab A/S News

Bicara Therapeutics price target lowered to $37 from $39 at BTIG

Genmab reports 9M revenue $3.24B vs. $2.66B last year

Genmab backs 2026 financial guidance

Genmab: Positive Phase III Results and Pipeline Potential Drive Price Target Raise to $4,400

Genmab price target raised to DKK 4,400 from DKK 4,200 at BofA

Genmab price target raised to $57 from $42 at Morgan Stanley

Genmab price target raised to $80 from $58 at Guggenheim

Bicara Therapeutics downgraded to Sell at Goldman on lower ficera outlook

Bicara Therapeutics price target lowered to $24 from $33 at Wedbush

Genmab price target raised to $70 from $50 at H.C. Wainwright

Genmab rises 29.2%

Genmab: Advancing Oncology Assets Support Buy Rating and Unchanged $50 Price Target

Genmab: Robust Oncology Data Drive Buy Rating and Price Target Increase to 3,200 DKK

Genmab Maintained at Buy as DARZALEX Strength and Oncology Pipeline Support Unchanged $50 Price Target

GE9 FAQ

Company Description

Genmab A/S

Genmab A/S (GE9) Earnings & Revenues

GE9 Stock 12 Month Forecast

Average Price Target

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium